公开(公告)号：WO2011101716A2

公开(公告)日：2011-08-25

申请号：PCT/IB2011/000128

申请日：2011-01-31

Applicant: COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH ,  KASHYAP, Sudhir, Kumar ,  SINHA, Amalendu

Inventor： KASHYAP, Sudhir, Kumar ,  SINHA, Amalendu

IPC: E21D15/14

CPC classification number: E21D15/46 ,  E21D15/56 ,  E21D15/581 ,  E21D15/585

Abstract: The present invention provides a device useful for supporting underground mine/ tunnels. The device continuously monitors the roof load coming over the canopy and correspondingly yielding/convergence indicated by the pointer on graduate scale. The roof load coming on the canopy is transmitted to the prop via a set of steel disc springs to increase the yielding and longevity of the present device. The present invention has mechanism for preloading upto the desired load. It is a simple, easily transportable and user friendly device having quick release mechanism from a safe distance.

Abstract translation: 本发明提供一种用于支撑地下矿井/隧道的装置。 该装置连续地监测通过冠层的屋顶负载，并且相应地由指针在指示器上产生/收敛。 通过一组钢盘弹簧将顶篷上的载荷传递到支柱，以增加本装置的屈服和寿命。 本发明具有预加载到所需负载的机构。 它是一个简单，易于运输和用户友好的设备，具有安全距离的快速释放机制。

公开(公告)号：WO2010150281A2

公开(公告)日：2010-12-29

申请号：PCT/IN2010/000428

申请日：2010-06-22

Applicant: PANACEA BIOTEC LTD. ,  JAIN, Rajesh ,  TREHAN, Sanjay ,  DAS, Jagattaran ,  KAUR, Gurmeet ,  KANWAR, Sandeep ,  SINGH, Nishan ,  NANDA, Gurmeet Kaur ,  MAGADI, Sitaram Kumar ,  SHARMA, Sudhir Kumar

Inventor： JAIN, Rajesh ,  TREHAN, Sanjay ,  DAS, Jagattaran ,  KAUR, Gurmeet ,  KANWAR, Sandeep ,  SINGH, Nishan ,  NANDA, Gurmeet Kaur ,  MAGADI, Sitaram Kumar ,  SHARMA, Sudhir Kumar

IPC: C07D221/22 ,  C07D401/10 ,  C07D413/10 ,  C07D413/14 ,  C07D417/10 ,  C07D471/04 ,  C07D491/08 ,  A61K31/46 ,  A61K31/496 ,  A61K31/498 ,  A61K31/5355 ,  A61K31/551 ,  C07D487/04 ,  A61P25/00 ,  A61P31/00

CPC classification number: C07D221/22 ,  C07D209/52 ,  C07D401/10 ,  C07D409/04 ,  C07D413/10 ,  C07D413/14 ,  C07D417/10 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D491/08

Abstract: The present invention relates to novel compounds of Formula (I), their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers including R and S isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof.

Abstract translation: 本发明涉及式（I）的新化合物，其药学上可接受的衍生物，互变异构体，立体异构体，包括R和S异构体，多晶型物，前药，代谢物，盐或溶剂化物。 本发明还涉及合成式I的新化合物，其药学上可接受的衍生物，互变异构体形式，立体异构体，多晶型物，前药，代谢物，盐或溶剂合物的方法。

公开(公告)号：WO2008010686A1

公开(公告)日：2008-01-24

申请号：PCT/KR2007/003516

申请日：2007-07-20

Applicant: SAMSUNG ELECTRONICS CO., LTD. ,  BAGHEL, Sudhir Kumar ,  VADLAPUDI, Tirumala Sree Hari Vara Prasad

Inventor： BAGHEL, Sudhir Kumar ,  VADLAPUDI, Tirumala Sree Hari Vara Prasad

IPC: H04B7/26

CPC classification number: H04W74/0866

Abstract: The invention relates to telecommunication systems and in particular to a method and system for efficient connection setup procedure for mobile terminated calls. A method of connection setup for mobile terminated calls is proposed in which a page message originating from the access network contains one access sequence along with access terminal identity or unicast access terminal identifier (UATI) of the paged access terminal. When more than one access terminal uses the same access sequence for sending their access probe at the same time a collision may occur. Access network selects access sequences from a reserved pool to direct the paged access terminal for performing access attempt to avoid collisions during access attempts. With this resource pooling, there is no need to send bind request and hence connection setup time reduces.

Abstract translation: 本发明涉及电信系统，尤其涉及用于移动终端呼叫的有效连接建立过程的方法和系统。 提出了一种用于移动终端呼叫的连接建立方法，其中从接入网发起的寻呼消息包含寻呼接入终端的接入终端身份或单播接入终端标识符（UATI）的一个接入序列。 当多个接入终端同时使用相同的接入序列发送其接入探测时，可能会发生冲突。 接入网络从保留池中选择接入序列，以指导寻呼接入终端执行接入尝试，以避免接入尝试期间的冲突。 使用此资源池，不需要发送绑定请求，因此连接建立时间减少。

公开(公告)号：WO2006029075A8

公开(公告)日：2007-04-26

申请号：PCT/US2005031532

申请日：2005-09-06

Applicant: REDDYS LAB LTD DR ,  REDDYS LAB INC DR ,  DAS SAIBAL KUMAR ,  SINGH SUNIL KUMAR ,  MADHAVAN GURRAM RANGA ,  BHUNIYA DEBNATH ,  IQBAL JAVED ,  SHARMA SUDHIR KUMAR ,  CHAKRABARTI RANJAN

Inventor： DAS SAIBAL KUMAR ,  SINGH SUNIL KUMAR ,  MADHAVAN GURRAM RANGA ,  BHUNIYA DEBNATH ,  IQBAL JAVED ,  SHARMA SUDHIR KUMAR ,  CHAKRABARTI RANJAN

IPC: A61K31/519 ,  C07D487/02

CPC classification number: C07D487/04 ,  C07D239/90

Abstract: There are provided derivatives having PPAR agonist activity. The derivatives include compounds and/or their pharmaceutically acceptable salts; the compounds having the formula (I) wherein A has the structure (II) or (III); X is chosen from -CH 2 -, -O-, -NH-, and -S-; Y is chosen from -O-, -NH-, and -S-; Z, which may be located in any position of substitution, is hydrogen or halogen; R 1 and R 2 , which may be the same or different, are independently chosen from hydrogen and C 1 -C 8 alkyl, or R 1 and R 2 together form a carbocyclic ring having from 4 to 6 carbon atoms; R 3 is chosen from hydrogen and C 1 -C 8 alkyl; R 4 , R 5 , and R 6 , which may be the same or different, are independently chosen from hydrogen and C 1 -C 8 alkyl; and n is 1 to 6. Various embodiments and variants are provided. In accordance with other aspects, the invention also provides methods of producing a PPARa agonist activity in a mammal, the methods including administering to the mammal an effective amount of certain derivative(s) of the first aspect of the invention, a method of producing a PPARa agonist activity and a PPARa agonist activity in a mammal, the method including administering to the mammal an effective amount of certain derivative(s); and a pharmaceutical composition that includes the derivative(s) of the first aspect of the invention and one or more pharmaceutically-acceptable excipients. Various embodiments and variants are provided.

Abstract translation: 提供了具有PPAR激动剂活性的衍生物。 衍生物包括化合物和/或其药学上可接受的盐; 其中A具有结构（II）或（III）的具有式（I）的化合物; X选自-CH 2 - ， - O - ， - NH-和-S-; Y选自-O - ， - NH-和-S-; 可以位于任何取代位置的Z是氢或卤素; R 1和R 2可以相同或不同，独立地选自氢和C 1 -C 8烷基， 烷基或R 1和R 2一起形成具有4至6个碳原子的碳环; R 3选自氢和C 1 -C 8烷基; R 3选自氢和C 1 -C 8烷基; R 4，R 5和R 6可以相同或不同，独立地选自氢和C 1 -C 4烷基， -C 8烷基; 并且n是1至6.提供了各种实施例和变体。 根据其它方面，本发明还提供了在哺乳动物中产生PPARα激动剂活性的方法，所述方法包括向哺乳动物施用有效量的本发明第一方面的某些衍生物，产生 PPARα激动剂活性和PPARα激动剂活性，所述方法包括给哺乳动物施用有效量的某些衍生物; 以及包含本发明第一方面的衍生物和一种或多种药学上可接受的赋形剂的药物组合物。 提供了各种实施例和变体。

公开(公告)号：WO2006029075A2

公开(公告)日：2006-03-16

申请号：PCT/US2005031532

申请日：2005-09-06

Applicant: REDDYS LAB LTD DR ,  REDDYS LAB LTD DR ,  DAS SAIBAL KUMAR ,  SINGH SUNIL KUMAR ,  MADHAVAN GURRAM RANGA ,  BHUNIYA DEBNATH ,  IQBAL JAVED ,  SHARMA SUDHIR KUMAR ,  CHAKRABARTI RANJAN

Inventor： DAS SAIBAL KUMAR ,  SINGH SUNIL KUMAR ,  MADHAVAN GURRAM RANGA ,  BHUNIYA DEBNATH ,  IQBAL JAVED ,  SHARMA SUDHIR KUMAR ,  CHAKRABARTI RANJAN

IPC: A61K31/519 ,  C07D487/02

CPC classification number: C07D487/04 ,  C07D239/90

Abstract: There are provided derivatives having PPAR agonist activity. The derivatives include compounds and/or their pharmaceutically acceptable salts; the compounds having the formula (I) wherein A has the structure (II) or (III); X is chosen from -CH 2 -, -O-, -NH-, and -S-; Y is chosen from -O-, -NH-, and -S-; Z, which may be located in any position of substitution, is hydrogen or halogen; R 1 and R 2 , which may be the same or different, are independently chosen from hydrogen and C 1 -C 8 alkyl, or R 1 and R 2 together form a carbocyclic ring having from 4 to 6 carbon atoms; R 3 is chosen from hydrogen and C 1 -C 8 alkyl; R 4 , R 5 , and R 6 , which may be the same or different, are independently chosen from hydrogen and C 1 -C 8 alkyl; and n is 1 to 6. Various embodiments and variants are provided. In accordance with other aspects, the invention also provides methods of producing a PPARa agonist activity in a mammal, the methods including administering to the mammal an effective amount of certain derivative(s) of the first aspect of the invention, a method of producing a PPARa agonist activity and a PPARa agonist activity in a mammal, the method including administering to the mammal an effective amount of certain derivative(s); and a pharmaceutical composition that includes the derivative(s) of the first aspect of the invention and one or more pharmaceutically-acceptable excipients. Various embodiments and variants are provided.

Abstract translation: 提供具有PPAR激动剂活性的衍生物。 衍生物包括化合物和/或其药学上可接受的盐; 具有式（I）的化合物其中A具有结构（II）或（III）; X选自-CH 2 - ， - O - ， - N - 和-S-; Y选自-O - ， - NH-和-S-; 可以位于任何取代位置的Z是氢或卤素; R 1和R 2可以相同或不同，独立地选自氢和C 1 -C 8烷基， 或者R 1和R 2一起形成具有4至6个碳原子的碳环; R 3选自氢和C 1 -C 8烷基; R 4，R 5，R 5和R 6可以相同或不同，独立地选自氢和C 1 C 8 -C 14烷基; 并且n为1至6.提供了各种实施方案和变体。 根据其它方面，本发明还提供了在哺乳动物中产生PPARα激动剂活性的方法，所述方法包括向哺乳动物施用有效量的本发明第一方面的某些衍生物， PPARα激动剂活性和PPARα激动剂活性，所述方法包括向哺乳动物施用有效量的某些衍生物; 和包含本发明第一方面的衍生物和一种或多种药学上可接受的赋形剂的药物组合物。 提供了各种实施例和变型。

公开(公告)号：WO2005040104A1

公开(公告)日：2005-05-06

申请号：PCT/IB2004/000208

申请日：2004-01-29

Applicant: DR. REDDY'S LABORATORIES LTD. ,  GURRAM, Ranga, Madhavan ,  BHUNIYA, Debnath ,  DAS, Saibal, Kumar ,  CHAKRABARTI, Ranjan ,  IQBAL, Javed ,  SHARMA, Sudhir, Kumar

Inventor： GURRAM, Ranga, Madhavan ,  BHUNIYA, Debnath ,  DAS, Saibal, Kumar ,  CHAKRABARTI, Ranjan ,  IQBAL, Javed ,  SHARMA, Sudhir, Kumar

IPC: C07C323/09

CPC classification number: C07C69/757 ,  C07B2200/07 ,  C07C33/28 ,  C07C59/68 ,  C07C67/30 ,  C07C67/31 ,  C07C69/712 ,  C07C217/84 ,  C07C309/66 ,  C07C323/52 ,  C07C2601/08 ,  C07C2603/18 ,  C07D233/64 ,  C07D265/38 ,  C07D279/22

Abstract: The present invention relates to novel hypolipidemic, antiobesity, hypocholesterolemic and antidiabetic compounds. More particularly, the present invention relates to novel alkyl carboxylic acids of the general formula (I), their stereoisomers, pharmaceutically acceptable salts thereof and pharmaceutical compositions containing them where all symbols are as defined in the description.

Abstract translation: 本发明涉及新型降血脂，抗肥胖，低胆固醇血症和抗糖尿病化合物。 更具体地，本发明涉及通式（I）的新型烷基羧酸，其立体异构体，其药学上可接受的盐和含有它们的药物组合物，其中所有符号如说明书中所定义。

公开(公告)号：WO2003014639A1

公开(公告)日：2003-02-20

申请号：PCT/GB2002/003638

申请日：2002-08-07

Applicant: THE BOC GROUP PLC ,  ALAMORIAN, Robert, Mathew ,  NAUMOVITZ, Joseph, Paul ,  PHAKEY, Sudhir, Kumar ,  RATHBONE, Thomas

Inventor： ALAMORIAN, Robert, Mathew ,  NAUMOVITZ, Joseph, Paul ,  PHAKEY, Sudhir, Kumar ,  RATHBONE, Thomas

IPC: F25J3/04

CPC classification number: F25J3/04284 ,  F25J3/04048 ,  F25J3/042 ,  F25J3/04296 ,  F25J3/04321 ,  F25J3/04393 ,  F25J3/044 ,  F25J3/04412 ,  F25J2200/54 ,  F25J2200/72 ,  F25J2235/02 ,  F25J2245/02 ,  F25J2245/42 ,  F25J2250/20

Abstract: Air is separated in a single fractionation column (116) to produce a top nitrogen gaseous fraction (142) and a bottom liquid fraction (120) containing less than (80) mole per cent of oxygen. A liquid nitrogen product (136) is also produced. The necessary refrigeration is created by expansion with the performance of external work of firstly a stream of compressed air in an expansion turbine (114) and of secondly a stream of vaporised bottom fraction in an expansion turbine (128). At least part of the feed to the column (116) comes from the turbine (114). The outlet pressure of the turbine (114) is essentially the gaseous nitrogen product pressure. A double fractionation column may be used instead of the single fractionation column (116).

Abstract translation: 空气在单个分馏塔（116）中分离以产生顶部氮气体馏分（142）和含有少于（80）摩尔％氧气的底部液体馏分（120）。 还生产液氮产物（136）。 通过在膨胀涡轮机（114）中首先进行压缩空气流的外部作业的膨胀和其次在膨胀涡轮机（128）中蒸发的底部馏分物流的膨胀来产生必要的制冷。 塔（116）的进料的至少一部分来自涡轮机（114）。 涡轮机（114）的出口压力基本上是氮气产物压力。 可以使用双分馏塔代替单分馏塔（116）。

公开(公告)号：WO2021077392A1

公开(公告)日：2021-04-29

申请号：PCT/CN2019/113245

申请日：2019-10-25

Applicant: QUALCOMM INCORPORATED ,  GUO, Hui ,  BAGHEL, Sudhir Kumar ,  GULATI, Kapil ,  WU, Shuanshuan ,  NGUYEN, Tien Viet ,  SARKIS, Gabi

Inventor： GUO, Hui ,  BAGHEL, Sudhir Kumar ,  GULATI, Kapil ,  WU, Shuanshuan ,  NGUYEN, Tien Viet ,  SARKIS, Gabi

IPC: H04L1/18

Abstract: Some aspects described herein relate to determining, by a transmitter user equipment (UE) in sidelink communications with a receiver UE, a feedback forwarding timing capability based at least in part on a first timing for receiving and processing feedback from the receiver UE, and indicating, to an access point, the feedback forwarding timing capability. Other aspects relate to determining, by a transmitter UE in sidelink communications with a receiver UE, a timing capability for the receiver UE to at least one of receive sidelink communications from the transmitter UE or report feedback for the sidelink communications to the transmitter UE.

公开(公告)号：WO2021068916A1

公开(公告)日：2021-04-15

申请号：PCT/CN2020/120106

申请日：2020-10-10

Applicant: QUALCOMM INCORPORATED ,  GUO, Hui ,  BAGHEL, Sudhir Kumar ,  NGUYEN, Tien Viet

Inventor： GUO, Hui ,  BAGHEL, Sudhir Kumar ,  NGUYEN, Tien Viet

IPC: H04L1/16 ,  H04L1/18

Abstract: Techniques for handling sidelink feedback signaling in situations where collisions would otherwise be experienced in a network communication link are shown and described. For example, sidelink feedback signaling handling techniques may provide for collision handling when sidelink HARQ is to be simultaneously transmitted with network communication radio interface uplink channel information (e.g., Uu HARQ, SR, CSI, etc. ) on one or more Uu channel (e.g., PUCCH, PUSCH, etc. ). In operation of sidelink feedback handling, a transmitter or intermediary UE of a sidelink communication link may decide whether and how to forward the sidelink HARQ to a corresponding base station. Other aspects and features are also claimed and described.

公开(公告)号：WO2013038429A3

公开(公告)日：2013-11-28

申请号：PCT/IN2012000612

申请日：2012-09-12

Applicant: PANACEA BIOTEC LTD ,  JAIN RAJESH ,  TREHAN SANJAY ,  DAS JAGATTARAN ,  NANDA GURMEET KAUR ,  THUNGATHURTHI SASTRY V R S ,  SINGH NISHAN ,  SHARMA SUDHIR KUMAR

Inventor： JAIN RAJESH ,  TREHAN SANJAY ,  DAS JAGATTARAN ,  NANDA GURMEET KAUR ,  THUNGATHURTHI SASTRY V R S ,  SINGH NISHAN ,  SHARMA SUDHIR KUMAR

IPC: A61P3/04 ,  A61P3/06 ,  A61P3/10

CPC classification number: C07D309/10 ,  C07D493/08 ,  C07H7/04

Abstract: The present invention relates to novel compounds of Formula (I), their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula (I), their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising novel compounds of Formula (I) and methods of treating or preventing one or more conditions or diseases that may be regulated or normalized via inhibition of Sodium Glucose Cotransporter-2 (SGLT-2).

Abstract translation: 本发明涉及式（I）的新化合物，其药学上可接受的衍生物，互变异构形式，异构体，多晶型物，前药，代谢物，盐或溶剂化物。 本发明还涉及合成式（I）的新化合物，其药学上可接受的衍生物，互变异构形式，异构体，多晶型物，前药，代谢物，盐或溶剂合物的方法。 本发明还提供了包含式（I）的新化合物的药物组合物以及治疗或预防可通过抑制葡萄糖协同转运蛋白-2（SGLT-2）而调节或正常化的一种或多种病症或疾病的方法。